Table 4.
DMD treatment use among female patients according to their plans to conceive.
| Plan to conceive | p-valuea | ||||||
|---|---|---|---|---|---|---|---|
| DMD typeb | No plan (n = 108) | Short-termc (n = 54) | Medium-termd (n = 44) | N/A (n = 44) | No plan vs. short-term plan | No plan vs. medium-term plan | Short-term vs. medium-term plan |
| Injectable therapies, n (%) |
19 (17.6) |
19 (35.2) |
9 (20.5) |
7 (15.9) |
0.013 | 0.680 | 0.108 |
| Oral therapies, n (%) |
34 (31.5) |
13 (24.1) |
15 (34.1) |
14 (31.8) |
0.327 | 0.755 | 0.275 |
| Infusion therapy, n (%) |
41 (38) |
16 (29.6) |
14 (31.8) |
17 (38.6) |
0.295 | 0.475 | 0.815 |
| Other, n (%) |
14 (13) |
6 (11.1) |
6 (13.6) |
6 (13.6) |
0.736 | 0.911 | 0.704 |
Pearson's chi-squared test at significance level 0.05, two-sided;
See Methods for DMD groups;
< 2 years;
≥2 years.
The Swiss SmPC for each DMD gives the following recommendations for women of childbearing age:(23) IFN β/glatiramer acetate/DMF, use a reliable contraception method; natalizumab, if pregnancy occurs, therapy cessation should be considered; fingolimod, use a reliable contraception method during therapy and within 2 months of therapy cessation; teriflunomide, use a reliable contraception method and must not be applied in pregnancy (can only become pregnant if teriflunomide blood concentration is < 0.02 mg/L).
DMD, disease modifying drug; DMF, dimethyl fumarate; n, number; N/A, not applicable.